Literature DB >> 12401680

Novel endpoints and design of early clinical trials.

W R Parulekar1, E A Eisenhauer.   

Abstract

Mesh：

Year:  2002        PMID： 12401680     DOI： 10.1093/annonc/mdf651

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

Review 1.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

2.  Pediatric phase I trial design using maximum target inhibition as the primary endpoint.

Authors:  Holly Meany; Frank M Balis; Alberta Aikin; Patricia Whitcomb; Robert F Murphy; Seth M Steinberg; Brigitte C Widemann; Elizabeth Fox
Journal:  J Natl Cancer Inst       Date:  2010-05-11       Impact factor: 13.506

Review 3.  New target-based agents involve new clinical trial designs.

Authors:  Coralia Bueno Muíño; José Angel García-Sáenz; Sara López Tarruella; Laura Rodríguez Lajustica; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

Review 4.  Current molecular imaging of spinal tumors in clinical practice.

Authors:  Nora Sandu; Gabriele Pöpperl; Marie-Elisabeth Toubert; Toma Spiriev; Belachew Arasho; Mikael Orabi; Bernhard Schaller
Journal:  Mol Med       Date:  2011-01-03       Impact factor: 6.354

5.  Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome.

Authors:  K S Ramcharan; G Y H Lip; P S Stonelake; A D Blann
Journal:  Int J Colorectal Dis       Date:  2015-01-20       Impact factor: 2.571

6.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

7.  Increasing complexity in oncology phase I clinical trials.

Authors:  Laeeq Malik; David Lu
Journal:  Invest New Drugs       Date:  2018-11-16       Impact factor: 3.850

8.  The changing face of phase 1 cancer clinical trials: new challenges in study requirements.

Authors:  Barbara S Craft; Razelle Kurzrock; Xiudong Lei; Roy Herbst; Scott Lippman; Siqing Fu; Daniel D Karp
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

9.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

10.  Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.

Authors:  Alma Chavez-Blanco; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Lucely Cetina; Myrna Candelaria; David Cantu; Aurora Gonzalez-Fierro; Patricia Garcia-Lopez; Pilar Zambrano; Carlos Perez-Plasencia; Gustavo Cabrera; Catalina Trejo-Becerril; Enrique Angeles; Alfonso Duenas-Gonzalez
Journal:  Mol Cancer       Date:  2005-07-07       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.